| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/PATH.1916 |
| P698 | PubMed publication ID | 16429394 |
| P50 | author | Emad A. Rakha | Q55098175 |
| Ian Ellis | Q55300055 | ||
| Andrew Green | Q55098173 | ||
| P2093 | author name string | Robertson JF | |
| Lee AH | |||
| Putti TC | |||
| Powe DG | |||
| Paish C | |||
| Abd El-Rehim DM | |||
| P2860 | cites work | Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome | Q24684801 |
| Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells | Q42085277 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 495-506 | |
| P577 | publication date | 2006-03-01 | |
| P1433 | published in | Journal of Pathology | Q400296 |
| P1476 | title | Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation | |
| P478 | volume | 208 |
| Q36369621 | A comprehensive morphological study for basal-like breast carcinomas with comparison to nonbasal-like carcinomas |
| Q39436586 | A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer |
| Q42485649 | A subset of breast cancer predisposes to brain metastasis |
| Q42438922 | A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard |
| Q42754959 | Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1α regulation in human breast cancer. |
| Q42486315 | Among triple-negative breast cancers, HER2(0) breast cancer shows a strong tendency to be basal-like compared with HER2(1+) breast cancer: preliminary results |
| Q42476461 | Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers |
| Q46326774 | Aquaporin 1 expression in invasive breast carcinomas |
| Q46354483 | Basal and myoepithelial phenotype of metastatic mammary carcinomas. A prognostic factor in the palliative situation? |
| Q35931900 | Basal breast cancer: a complex and deadly molecular subtype |
| Q37853555 | Basal phenotype breast cancer: implications for treatment and prognosis |
| Q35749421 | Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival |
| Q34512811 | Basal-like phenotype in a breast carcinoma case series from Sudan: prevalence and clinical/pathological correlations |
| Q35749393 | Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. |
| Q42698539 | Bioconjugated graphene oxide-based Raman probe for selective identification of SKBR3 breast cancer cells |
| Q37328394 | Biomarkers for Basal-like Breast Cancer |
| Q26773761 | Breast cancer intrinsic subtype classification, clinical use and future trends |
| Q45852595 | CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy. |
| Q37338128 | Calretinin expression in high-grade invasive ductal carcinoma of the breast is associated with basal-like subtype and unfavorable prognosis |
| Q37188273 | Cancer stem cells in breast: current opinion and future challenges. |
| Q40809878 | Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. |
| Q35678658 | Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response |
| Q37400389 | Chromosomal changes in aggressive breast cancers with basal-like features |
| Q51036885 | Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens. |
| Q42496885 | Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein |
| Q37062876 | Clinical and pathologic aspects of basal-like breast cancers |
| Q37137019 | Clinical proteomics and breast cancer: strategies for diagnostic and therapeutic biomarker discovery |
| Q33885885 | Clinical proteomics of breast cancer |
| Q35483406 | Clinical significance of morphologic characteristics in triple negative breast cancer |
| Q34465749 | Clinicopathologic characteristics of typical medullary breast carcinoma: a retrospective study of 117 cases |
| Q42474341 | Clinicopathological features and treatment strategy for triple-negative breast cancer |
| Q92740158 | Competing Risk Analyses of Medullary Carcinoma of Breast in Comparison to Infiltrating Ductal Carcinoma |
| Q55259549 | Cutaneous Adnexal Cylindroma of Breast: Epithelial Immunoreactivities for GATA-3, Mammaglobin, and E-Cadherin Do Not Equate to a Mammary Ductal Neoplasm. |
| Q42453543 | Cytological criteria to predict basal phenotype of breast carcinomas. |
| Q36554684 | Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients |
| Q36172507 | Demystifying basal-like breast carcinomas |
| Q34773994 | Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC. |
| Q37225635 | Difference in characteristics and outcomes between medullary breast carcinoma and invasive ductal carcinoma: a population based study from SEER 18 database |
| Q89536167 | Double-positive in triple-negative? How significant is basal cytokeratin expression in breast cancer? |
| Q53666394 | EMT, cell plasticity and metastasis. |
| Q42496058 | EpCAM expression is an indicator of recurrence in basal-like breast cancer |
| Q38765639 | Epigenetic regulation of soluble guanylate cyclase (sGC) β1 in breast cancer cells |
| Q26859804 | Epithelial-mesenchymal plasticity in carcinoma metastasis |
| Q37744737 | Epithelial-to-mesenchymal transitions and circulating tumor cells |
| Q42489213 | Estrogen receptor-alpha promoter methylation in sporadic basal-like breast cancer of Chinese women |
| Q42485213 | Evaluation of carcinogenic potential of diuron in a rat mammary two-stage carcinogenesis model. |
| Q42450410 | Expression and prognostic significance of CK19 in canine malignant mammary tumours |
| Q47687311 | Expression of GHRH-R, a Potentially Targetable Biomarker, in Triple-negative Breast Cancer |
| Q35040780 | Expression of NgBR is highly associated with estrogen receptor alpha and survivin in breast cancer |
| Q42497489 | Expression of calretinin by breast carcinoma and the potential for misdiagnosis of mesothelioma |
| Q34566972 | Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients |
| Q84023451 | Fine-needle aspiration cytology of low-grade adenosquamous carcinoma of the breast |
| Q46128572 | Further evidence that E-cadherin is not a tumour suppressor gene in invasive ductal carcinoma of the breast: an immunohistochemical study |
| Q35832016 | Genetic characterization of breast cancer and implications for clinical management |
| Q48674329 | Genome-wide expression profiling as a clinical tool: are we there yet? |
| Q42484093 | High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma. |
| Q37639896 | Histological and molecular types of breast cancer: is there a unifying taxonomy? |
| Q42473472 | Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast |
| Q36587555 | Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation |
| Q37746023 | Histological types of breast cancer: how special are they? |
| Q42439751 | Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. |
| Q42439372 | Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). |
| Q42519161 | Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). |
| Q36845026 | Immunohistochemical profile of high-grade ductal carcinoma in situ of the breast. |
| Q42503707 | Immunohistochemical study of metaplastic carcinoma and central acellular carcinoma of the breast: central acellular carcinoma is related to metaplastic carcinoma |
| Q42524653 | Independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI-1. |
| Q42511044 | Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35. |
| Q36086823 | KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer |
| Q42480779 | Large-cell lung carcinoma with basaloid architecture and neuroendocrine differentiation: a new type of combined large-cell neuroendocrine carcinoma |
| Q42484870 | Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance |
| Q40962515 | Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification. |
| Q33317058 | Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin |
| Q34980398 | Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer |
| Q42465107 | May metaplastic breast carcinomas be actually basal-like carcinoma? Further evidence study with its ultrastructure and survival analysis |
| Q37339008 | Mesothelin expression and survival outcomes in triple receptor negative breast cancer |
| Q37134884 | Mesothelin, a novel immunotherapy target for triple negative breast cancer |
| Q37293236 | Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer |
| Q42510147 | Metabolism-related proteins are differentially expressed according to the molecular subtype of invasive breast cancer defined by surrogate immunohistochemistry |
| Q37356684 | Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet? |
| Q37401549 | Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival |
| Q41130064 | Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort |
| Q37974614 | Molecular classification of breast carcinomas with particular emphasis on "basal-like" carcinoma: a critical review |
| Q34667729 | Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy |
| Q34123314 | Molecular insights on basal-like breast cancer |
| Q34577467 | Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. |
| Q34248718 | Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically |
| Q48189942 | Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers |
| Q50530893 | Objective assessment of lymphatic and blood vascular invasion in lymph node-negative breast carcinoma: findings from a large case series with long-term follow-up. |
| Q36095980 | Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients |
| Q42504332 | P-cadherin expression and basal-like subtype in breast cancers |
| Q36458759 | P-cadherin expression in breast cancer: a review |
| Q34748822 | Predictive value of pathological and immunohistochemical parameters for axillary lymph node metastasis in breast carcinoma |
| Q42513522 | Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer |
| Q36337755 | Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials |
| Q35840060 | Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population |
| Q42505075 | Prognostic markers in triple-negative breast cancer |
| Q33245053 | Proteomics of breast cancer: principles and potential clinical applications |
| Q60954594 | Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants |
| Q35551849 | Role of microRNA221 in regulating normal mammary epithelial hierarchy and breast cancer stem-like cells |
| Q35944076 | SMAD4 expression in breast ductal carcinoma correlates with prognosis |
| Q39019431 | SUMOylation proteins in breast cancer |
| Q42509097 | Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer |
| Q50489396 | TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome. |
| Q28546094 | The active tamoxifen metabolite endoxifen (4OHNDtam) strongly down-regulates cytokeratin 6 (CK6) in MCF-7 breast cancer cells |
| Q35082260 | The changing role of pathology in breast cancer diagnosis and treatment |
| Q36172504 | The histological diagnosis of metastases to the breast from extramammary malignancies |
| Q45350621 | The microRNA maturation regulator Drosha is an independent predictor of outcome in breast cancer patients |
| Q34752938 | The molecular pathology of breast cancer progression |
| Q42489904 | The prognostic significance of B lymphocytes in invasive carcinoma of the breast. |
| Q64018926 | The prognostic significance of lymphovascular invasion in invasive breast carcinoma |
| Q36573836 | Tissue detection of biomolecular predictors in breast cancer |
| Q34433737 | Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer |
| Q34331406 | Treatment options for patients with triple-negative breast cancer |
| Q36024205 | Triple negative breast cancer - our experience and review |
| Q37602289 | Triple negative breast cancers: clinical and prognostic implications. |
| Q37764168 | Triple-negative breast cancer: present challenges and new perspectives |
| Q34275213 | Triple-negative breast carcinomas are a heterogeneous entity that differs between young and old patients |
| Q33801214 | Unique expression pattern of the three insulin receptor family members in the rat mammary gland: dominance of IGF-1R and IRR over the IR, and cyclical IGF-1R expression. |
| Q33291587 | Use of immunohistochemical markers can refine prognosis in triple negative breast cancer |
| Q37605859 | What's positive about 'triple-negative' breast cancer? |
| Q88687974 | Where youth matters-clinicopathologic characteristics and emerging trends in treatment and outcomes in young Irish women with breast cancer |
| Q36863171 | p16 expression correlates with basal-like triple-negative breast carcinoma |
| Q42468590 | p63 short isoforms are found in invasive carcinomas only and not in benign breast conditions |
Search more.